Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial

Tesamorelin, a synthetic growth hormone-releasing hormone, is indicated for the reduction of visceral adipose tissue (VAT) in people with HIV. Here, we performed a post hoc analysis of participants receiving tesamorelin for 26 weeks in a phase III clinical trial. Efficacy data were compared between...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahman, Farah, McLaughlin, Taryn, Mesquita, Pedro, Morin, Josee, Potvin, Diane, De Chantal, Marilyn, Aberg, Judith A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947601/
https://www.ncbi.nlm.nih.gov/pubmed/36845310
http://dx.doi.org/10.1017/cts.2022.515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947601/
https://www.ncbi.nlm.nih.gov/pubmed/36845310
http://dx.doi.org/10.1017/cts.2022.515

Ejemplares similares